Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies
PMID: 38797892
Source: Clin Pharmacol Ther
Publication date:
2025-07-24
Year:
2024
Abstract
NULL